Specialty

Since the rise of accumulator and maximizer programs, many stakeholders within the pharmacy industry have been looking to tip the scales back towards traditional copay assistance models.

By understanding your contract, communicating with your PBM, and working with a partner to craft your pharmacy strategy, you’ll be well prepared for the rise of biosimilar drugs.

How can you build more transparency in your pharmacy contract? We lay out five critical strategies to ensure you have control and oversight over your program.

In this Truveris webinar, we join Mployer Advisor to tackle pharmacy benefits 101. What should payers know about PBMs as they plan for 2023?

The gross-to-net bubble is inflating. What patient access strategies are leading brands using to combat this trend?

How should pharma companies plan for if their drugs will be included in accumulator or maximizer programs? Use our interactive checklist.

Truveris’ Pharmacy Benefits Glossary of Terms provides important definitions and context to help navigate the pharmacy benefits landscape.

As biosimilars gain more popularity in the market, pharma manufacturers must think differently about launch strategies to gain market share.

If you work in the pharmacy ecosystem, you’ve probably heard buzz around “biosimilars.” What should you know about this innovative type of medication?

6,000 pharmacy professionals attended Asembia this year. What were the key takeaways from the conference?

Plan sponsors are looking for new ways to contain specialty costs. How should they evaluate new copay assistance strategies?

As pharmacy costs increase, what are strategies plan sponsors can take to control specialty pharmacy spend?

Read Sally Welborn’s POV piece on the misaligned incentives at play in the pharmacy benefits ecosystem – and what it means for plan sponsors.

How are copay maximizers and alternative funding impacting plans – and members? Watch our on-demand webinar to learn more.

Four core themes from Asembia 2021 that will drive dialogue in the specialty pharmacy ecosystem in 2022 – and beyond.

340B is increasingly a part of the pharmacy conversation. How should stakeholders react to the program?

Many gene therapy products are soon to be released to the market. What do payers need to know about these highly-expensive specialty drugs?

Watch Truveris’ on-demand webinar outlining how Payers can best anticipate and manage new gene therapies.

Looking forward to the future of pharmacy, it’s critical to understand how a specialty drug is defined, how it differs from traditional, non-specialty drugs, and how specialty is impacting employers’ benefit plan designs.  

Watch Truveris’ webinar to learn more about how you can better manage a self-funded specialty pharmacy program.

Pharmacy Benefits Managers, also referred to as PBMs, are the intermediaries between every stakeholder in the pharmacy ecosystem.

Why type of plan sponsor could benefit from carving out their pharmacy plan?